Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer

Immunologic Research

Volumn 54, Issue 1-3, 2012, Pages 266-274

  Tong, Charles C L ^a   Kao, Johnny ^b   Sikora, Andrew G ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Good Samaritan Hospital Medical Center   (United States)

^c Tisch Cancer Institute   (United States)

Author keywords

Head and neck squamous cell carcinoma (HNSCC); Immune suppression; Immunotherapy; Myeloid derived suppressive cells (MDSC); Regulatory T cells; Tumor immunology; Tumor infiltrating lymphocytes; Tumor mediated immunosuppression

Indexed keywords

CELECOXIB; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CUTANEOUS MELANOMA; DRUG EFFICACY; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE DEFICIENCY; KIDNEY CARCINOMA; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; WART VIRUS;

ANIMALS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE TOLERANCE; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84867841670     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-012-8306-6     Document Type: Article

References (94)

1. Prince A, et al. Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med. 2010;77(6):684-99.
2. Choi HR, et al. Molecular and clinicopathologic comparisons of head and neck squamous carcinoma variants: common and distinctive features of biological significance. Am J Surg Pathol. 2004;28(10):1299-310.
3. Wang X, et al. Intratumor genomic heterogeneity correlates with histological grade of advanced oral squamous cell carcinoma. Oral Oncol. 2006;42(7):740-4.
4. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-50.
5. Papadimitrakopoulou VA, et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res. 2001;7(10):3127-34.
6. Poeta ML, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552-61.
7. Ragin CC, et al. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer. 2006;95(10):1432-8.
8. Grulich AE, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67.
9. King GN, et al. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med. 1995;332(16):1052-7.
10. van Leeuwen MT, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ. 2010;340:c570.
11. Vu HL, et al. HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett. 2010;288(2):149-55.
12. Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. 2005;33(2):113-33.
13. Meissner M, et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res. 2005;11(7):2552-60.
14. Albers AE, et al. T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Clin Dev Immunol. 2010;2010:236378.
15. Wang S, Chen L. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect. 2004;6(8):759-66.
16. Pries R, Nitsch S, Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 2006;6(9):1195-203.
17. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25(3):435-57.
18. Mocellin S, et al. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev. 2004;15(1):61-76.
19. Brandwein-Gensler M, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005;29(2):167-78.
20. Hosal AS, Unal OF, Ayhan A. Possible prognostic value of histopathologic parameters in patients with carcinoma of the oral tongue. Eur Arch Otorhinolaryngol. 1998;255(4):216-9.
21. Yan HH, et al. Gr-1+ CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 2010;70(15):6139-49.
22. Yang L, et al. Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6(4):409-21.
23. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239-52.
24. Hoffmann TK, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8(8):2553-62.
25. Reichert TE, et al. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002;8(10):3137-45.
26. Bian Y et al. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene, 2011.
27. Mantovani A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
28. Bronte V, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000;96(12):3838-46.
29. Kusmartsev S, et al. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172(2):989-99.
30. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174(2):636-45.
31. Murdoch C, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618-31.
32. Shojaei F, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007;450(7171):825-31.
33. Serafini P, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13):5439-49.
34. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-74.
35. Waight JD, et al. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS ONE. 2011;6(11):e27690.
36. Lissbrant IF, et al. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol. 2000;17(3):445-51.
37. Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999;57(2):138-42.
38. Tsutsui S, et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005;14(2):425-31.
39. Badoual C, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006;12(2):465-72.
40. Le QT, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol. 2005;23(35):8932-41.
41. Wolf GT, et al. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg. 1986;95(2):142-52.
42. Rajjoub S, et al. Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J. 2007;86(8):506-11.
43. Uppaluri R, Dunn GP, Lewis JS Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008;8:16.
44. Bergmann C, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res. 2008;14(12):3706-15.
45. Hartmann E, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003;63(19):6478-87.
46. Thiel A, et al. Expression of the T cell receptor alphabeta on a CD123+ BDCA2+ HLA-DR+ subpopulation in head and neck squamous cell carcinoma. PLoS ONE. 2011;6(1):e15997.
47. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31(6):744-54.
48. Hung CF, et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8(4):421-39.
49. van Driel WJ, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 1999;35(6):946-52.
50. Roman LD, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2007;106(3):558-66.
51. Murakami M, Gurski KJ, Steller MA. Human papillomavirus vaccines for cervical cancer. J Immunother. 1999;22(3):212-8.
52. Chikamatsu K, et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res. 1999;5(6):1281-8.
53. DeLeo AB. p53-based immunotherapy of cancer. Crit Rev Immunol. 1998;18(1-2):29-35.
54. Hoffmann TK, et al. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol. 2000;165(10):5938-44.
55. Ropke M, et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA. 1996;93(25):14704-7.
56. Song GY, et al. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother. 2007;56(8):1193-205.
57. Terlou A, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol. 2011;121(1):157-62.
58. van Seters M, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med. 2008;358(14):1465-73.
59. Gkoulioni V, et al. The efficacy of imiquimod on dysplastic lesions of the oral mucosa: an experimental model. Anticancer Res. 2010;30(7):2891-6.
60. Sacchi M, et al. Antiproliferative effects of cytokines on squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1991;117(3):321-6.
61. Cortesina G, et al. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer. 1988;62(12):2482-5.
62. Mantovani G, et al. Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2. Cancer Immunol Immunother. 1998;47(3):149-56.
63. Mattijssen V, et al. Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. J Immunother. 1991;10(1):63-8.
64. Almand B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6(5):1755-66.
65. Cheng P, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205(10):2235-49.
66. Corzo CA, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439-53.
67. LeCouter J, et al. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci USA. 2004;101(48):16813-8.
68. Pan PY, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008;111(1):219-28.
69. Nefedova Y, et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65(20):9525-35.
70. Ozao-Choy J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69(6):2514-22.
71. Porta C, et al. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer. 2011;2:333-8.
72. Choong NW, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010;28(5):677-83.
73. Fountzilas G, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol. 2010;65(4):649-60.
74. Machiels JP, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 2010;28(1):21-8.
75. Kao J, et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer. 2009;115(15):3571-80.
76. Ochoa AC, et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13(2 Pt 2):721s-6s.
77. Sinha P, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007;67(9):4507-13.
78. Talmadge JE, et al. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol. 2007;7(2):140-51.
79. Wirth LJ, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(28):6976-81.
80. Kao J, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer. 2011;117(14):3173-81.
81. Serafini P, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691-702.
82. Strauss L, et al. The frequency and suppressor function of CD4+ CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13(21):6301-11.
83. Josefowicz SZ, LF Lu, AY Rudensky, et al. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol, 2012.
84. Boucek J, et al. Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. J Cell Mol Med. 2010;14(1-2):426-33.
85. Cunningham DR. Observations on preprofessional education: is there a major difference? ASHA. 1991;33(1):37-9.
86. Watanabe Y, et al. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(5):744-52.
87. Airoldi M, et al. Ifosfamide in the treatment of head and neck cancer. Oncology. 2003;65(Suppl 2):37-43.
88. Sistigu A, et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33(4):369-83.
89. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37(5):430-9.
90. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
91. Azad AK, et al. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival. Clin Cancer Res. 2012;18(1):196-206.
92. Kammerer PW, et al. Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma. Oral Oncol. 2010;46(7):543-8.
93. Malaspina TS, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother. 2011;60(7):965-74.
94. Tsushima F, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 2006;42(3):268-74.